Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma
NCT00792467
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Hodgkin's Lymphoma
Interventions
DRUG:
ITF2357
Sponsor
Italfarmaco